Role of vasopressin antagonists in the management of acute decompensated heart failure.

被引：6
作者：
Orlandi C. [1 ]
Zimmer C.A. [1 ]
Gheorghiade M. [1 ]
机构：
[1] Department of Clinical Development, Otsuka Maryland Research Institute, Inc., 2440 Research Boulevard, Rockville, 20850, MD
来源：
Current Heart Failure Reports | 2005年 / 2卷 / 3期
关键词：
Vasopressin; Chronic Heart Failure; Serum Sodium; Pulmonary Capillary Wedge Pressure; Tolvaptan;
D O I：
10.1007/s11897-005-0021-3
中图分类号：
学科分类号：
摘要：
Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.
引用
收藏
页码：131 / 139
页数：8
相关论文
共 164 条
  • [1] Gheorghiade M(2004)Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure JAMA 291 1963-1971
  • [2] Gattis WA(2002)Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 1541-1547
  • [3] O’Connor CM(2002)Prognosis and determinants of survival in patients newly hospitalized for heart failure Arch Intern Med 162 1689-1694
  • [4] Cuffe MS(2002)Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure JAMA 287 1531-1540
  • [5] Califf RM(1997)Association between diuretic use, clinical response, and death in acute heart failure Am J Cardiology 80 519-522
  • [6] Adams KF(2004)The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure (CASINO) Study [Abstract 835-6] J Am Coll Cardiol 43 206A-206A
  • [7] Jong P(2000)Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995 Circulation 102 1126-1131
  • [8] Vowinckel E(2004)Trends in heart failure incidence and survival in a community-based population JAMA 292 344-350
  • [9] Liu PP(2002)Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry) Am Heart J 143 45-55
  • [10] Philbin EF(2003)Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial Circulation 107 2690-2696
12345678910